The Globe and Mail reports in its Tuesday, Dec. 17, edition that Canaccord Genuity analyst Neil Maruoka is sticking with his "hold" rating on Theratechnologies (49.5 cents). The Globe's Darcy Keith and Jody White write in the Eye On Equities column that Mr. Maruoka, however, hiked his price target by 35 cents to 65 cents. The analyst says an agreement that will once again give Theratechnologies United States marketing rights to the Egrifta drug is a significant positive for the company, providing it with improved economics and full control over the marketing strategy. Mr. Maruoka says, "Continued uncertainty around the potential for additional global approvals, and limited visibility of US Egrifta sales, tempers our view." The drug is being proposed for the treatment of excess abdominal fat in some HIV patients. The Globe says the average Street target is 55 cents. Loewen, Ondaatje, McCutcheon analyst Connie Chen said buy Theratechnologies in the Eye column on Jan. 15, 2009, and May 27, 2010, when it was worth $1.63 and $2.90. Mr. Maruoka cut his rating to "hold" from "buy" in the Eye column on Oct. 16, 2012. He shaved his target by $3.40 to 60 cents. The shares were then worth 46.5 cents.